What is China Sxt Pharmaceuticals Inc's earnings per share (EPS)?

China Sxt Pharmaceuticals Inc (SXTC) reported diluted earnings per share of -$9.13 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

China Sxt Pharmaceuticals Inc Financials

SXTC

FY2026 annual

Revenue $1.1M -34.6% YoY

Net Income -$6.2M -87.8% YoY

EPS (Diluted) -$9.13 YoY not available

Free Cash Flow Not reported for FY2026

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Mar 31, 2026 Reported Jul 1, 2026 Currency USD FYE March

China Sxt Pharmaceuticals Inc (SXTC) reported $1.1M in revenue for fiscal year 2026, down 34.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SXTC FY2026 2026-08-15

External financing, not operating cash generation, is carrying a shrinking business while cash accumulates on a lightly indebted balance sheet.

FY2026 cash of $28.2M versus liabilities of $5.05M gives the company substantial balance-sheet liquidity, but it does not make operations self-funding. Operating cash flow of -$4.02M alongside financing inflows of $14.4M shows that cash availability is being maintained externally rather than earned.

Revenue contracted 34.6% to $1.14M in FY2026, reducing the scale available to absorb overhead. SG&A was $7.13M, about 6.3x revenue, so the operating loss reflects a cost base far larger than current sales.

Gross margin held at 21.9%, indicating that the sharper deterioration occurred below gross profit rather than primarily in product costs. The operating margin reached -625.9%, making overhead absorption the dominant profitability constraint.

Financial Health Signals

Financial Health Score 33/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of China Sxt Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

Not available for China Sxt Pharmaceuticals Inc, and counted as zero in the overall score.

R&D Intensity

Not available for China Sxt Pharmaceuticals Inc, and counted as zero in the overall score.

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-0.79

China Sxt Pharmaceuticals Inc scores -0.79, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.6M) relative to total liabilities ($5.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

China Sxt Pharmaceuticals Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

China Sxt Pharmaceuticals Inc reported a net loss of $6.2M while operations used $4.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

China Sxt Pharmaceuticals Inc reported an operating loss of $7.1M against $63K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.1M

YoY-34.6%

5Y CAGR-24.9%

China Sxt Pharmaceuticals Inc generated $1.1M in revenue in fiscal year 2026. This represents a decrease of 34.6% from the prior year.

EBITDA

-$7.0M

YoY-171.3%

China Sxt Pharmaceuticals Inc's EBITDA was -$7.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 171.3% from the prior year.

Net Income

-$6.2M

YoY-87.8%

China Sxt Pharmaceuticals Inc reported -$6.2M in net income in fiscal year 2026. This represents a decrease of 87.8% from the prior year.

EPS (Diluted)

-$9.13

China Sxt Pharmaceuticals Inc earned -$9.13 per diluted share (EPS) in fiscal year 2026.

Cash & Balance Sheet

Cash & Debt

$28.2M

YoY+55.7%

5Y CAGR+16.1%

China Sxt Pharmaceuticals Inc held $28.2M in cash against $644K in long-term debt as of fiscal year 2026.

Shares Outstanding

958,077

China Sxt Pharmaceuticals Inc had 958,077 shares outstanding in fiscal year 2026.

Free Cash Flow

Not reported for fiscal year 2026.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Gross Margin

21.9%

YoY+0.7pp

5Y CAGR-37.6pp

China Sxt Pharmaceuticals Inc's gross margin was 21.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the prior year.

Return on Equity

-20.9%

YoY+0.5pp

5Y CAGR-3.7pp

China Sxt Pharmaceuticals Inc's ROE was -20.9% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 0.5 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

None of these metrics is reported for fiscal year 2026.

SXTC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SXTC quarterly income statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	$1.1M-34.6%	$1.7M-9.7%	$1.9M-2.2%	$2.0M-24.2%	$2.6M-45.5%	$4.8M-7.5%	$5.2M-26.4%	$7.0M-0.1%	$7.0M+43.8%	$4.9M
Cost of Revenue	$889K-35.2%	$1.4M-0.1%	$1.4M-11.1%	$1.5M+14.4%	$1.4M-30.3%	$1.9M-21.2%	$2.5M+2.4%	$2.4M-33.6%	$3.6M+40.8%	$2.6M
Gross Profit	$249K-32.3%	$367K-33.7%	$554K+30.0%	$426K-65.9%	$1.3M-55.9%	$2.8M+5.0%	$2.7M-41.4%	$4.6M+35.6%	$3.4M+47.1%	$2.3M
R&D Expenses	N/A	N/A	$184K-8.2%	$201K-45.3%	$367K	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$7.1M+158.4%	$2.8M+4.6%	$2.6M-53.3%	$5.6M+2.3%	$5.5M+59.9%	$3.4M+40.1%	$2.5M+99.1%	$1.2M-1.6%	$1.3M+122.3%	$565K
Operating Income	-$7.1M-165.7%	-$2.7M-6.6%	-$2.5M+55.1%	-$5.6M-8.1%	-$5.2M-136.2%	-$2.2M-63.8%	-$1.3M-175.8%	$1.8M+8.4%	$1.6M+1.9%	$1.6M
Interest Expense	$63K-40.7%	$106K-54.1%	$232K-51.4%	$477K+1199.3%	$37K-97.7%	$1.6M-51.8%	$3.3M+64623.4%	$5K+564.2%	$779-98.1%	$40K
Income Tax	N/A	N/A	N/A	N/A	$328K+270.3%	-$193K-89.4%	-$102K-140.3%	$252K-42.7%	$440K+11.4%	$395K
Net Income	-$6.2M-87.8%	-$3.3M-6.6%	-$3.1M+47.8%	-$5.9M-3.5%	-$5.7M-108.7%	-$2.7M+73.3%	-$10.3M-768.4%	$1.5M+29.6%	$1.2M+0.2%	$1.2M
EPS (Diluted)	-$9.13	-$348.17	-$4285.66	-$177.84	-$137.92	-$3.82	N/A	$0.07+27.1%	$0.060.0%	$0.06

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).

SXTC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SXTC quarterly balance sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$34.8M+60.4%	$21.7M-6.3%	$23.1M-21.7%	$29.6M-11.9%	$33.5M-2.9%	$34.5M+59.2%	$21.7M+24.2%	$17.5M+128.1%	$7.7M	N/A
Current Assets	$34.5M+62.0%	$21.3M+49.6%	$14.2M-27.1%	$19.5M-13.1%	$22.5M-3.4%	$23.2M+18.3%	$19.6M+26.0%	$15.6M+155.5%	$6.1M	N/A
Cash & Equivalents	$28.2M+55.7%	$18.1M+49.9%	$12.1M-30.5%	$17.4M+11.9%	$15.5M+16.4%	$13.3M+83.0%	$7.3M-21.6%	$9.3M+1312.6%	$658K+903.2%	$66K
Inventory	$777K-6.2%	$828K+4.2%	$795K+49.6%	$531K-47.8%	$1.0M+18.4%	$860K-3.7%	$893K-11.4%	$1.0M-20.4%	$1.3M	N/A
Accounts Receivable	$932K-28.4%	$1.3M-1.0%	$1.3M-2.2%	$1.3M-59.7%	$3.3M-26.0%	$4.5M+18.0%	$3.8M-8.6%	$4.2M+60.6%	$2.6M	N/A
Total Liabilities	$5.0M-18.9%	$6.2M-32.3%	$9.2M-38.1%	$14.9M-13.2%	$17.1M-7.9%	$18.6M+51.1%	$12.3M+93.3%	$6.4M+45.5%	$4.4M	N/A
Current Liabilities	$4.3M-27.7%	$6.0M-32.5%	$8.9M-38.6%	$14.5M-15.3%	$17.1M-7.8%	$18.6M+51.5%	$12.3M+94.0%	$6.3M+44.6%	$4.4M	N/A
Long-Term Debt	$644K+569.4%	$96K-17.8%	$117K-0.6%	$118K	N/A	$6K-82.8%	$37K-12.5%	$42K	N/A	N/A
Total Equity	$29.7M+92.4%	$15.4M+10.8%	$13.9M-5.2%	$14.7M-8.7%	$16.1M+0.8%	$16.0M+69.8%	$9.4M-15.4%	$11.1M+238.1%	$3.3M+77.4%	$1.9M
Retained Earnings	-$34.2M-22.1%	-$28.0M-13.4%	-$24.7M-14.3%	-$21.6M-37.8%	-$15.7M-57.6%	-$10.0M-38.1%	-$7.2M-333.6%	$3.1M+99.6%	$1.5M	N/A

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23
Total Assets	$34.8M+31.9%	$26.4M+21.6%	$21.7M-30.1%	$31.0M+34.0%	$23.1M+58.5%	$14.6M-50.6%	$29.6M+33.2%	$22.2M
Current Assets	$34.5M+32.5%	$26.0M+22.3%	$21.3M-3.1%	$22.0M+54.5%	$14.2M+5.5%	$13.5M-30.9%	$19.5M+57.9%	$12.4M
Cash & Equivalents	$28.2M+33.1%	$21.2M+16.9%	$18.1M-2.2%	$18.5M+53.4%	$12.1M+5.3%	$11.5M-34.0%	$17.4M+482.6%	$3.0M
Inventory	$777K+3.4%	$751K-9.3%	$828K-4.5%	$867K+9.1%	$795K+61.2%	$493K-7.2%	$531K-15.4%	$628K
Accounts Receivable	$932K-30.3%	$1.3M+2.7%	$1.3M-21.8%	$1.7M+26.6%	$1.3M+0.3%	$1.3M-2.5%	$1.3M-59.5%	$3.3M
Total Liabilities	$5.0M-17.5%	$6.1M-1.7%	$6.2M-61.0%	$16.0M+73.6%	$9.2M-3.3%	$9.5M-36.0%	$14.9M+103.8%	$7.3M
Current Liabilities	$4.3M-27.0%	$6.0M-0.8%	$6.0M-61.6%	$15.7M+76.0%	$8.9M-3.2%	$9.2M-36.5%	$14.5M+98.8%	$7.3M
Long-Term Debt	$644K+781.5%	$73K-24.1%	$96K-16.5%	$115K-1.5%	$117K+9.9%	$107K-9.6%	$118K	N/A
Total Equity	$29.7M+46.8%	$20.2M+31.0%	$15.4M+2.7%	$15.0M+7.9%	$13.9M+174.4%	$5.1M-65.4%	$14.7M+1.0%	$14.5M
Retained Earnings	-$34.2M+0.5%	-$34.4M-22.7%	-$28.0M-9.8%	-$25.5M-3.2%	-$24.7M+21.1%	-$31.3M-44.9%	-$21.6M-25.8%	-$17.2M

Not reported in any period shown, so not listed: Goodwill.

SXTC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SXTC quarterly cash flow statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$4.0M-71.3%	-$2.3M-21.6%	-$1.9M-2287.5%	-$81K-130.1%	$268K+120.4%	-$1.3M-240.9%	$934K+290.6%	$239K-87.5%	$1.9M+555.3%	$293K
Capital Expenditures	N/A	$2K-71.4%	$7K	N/A	N/A	N/A	$131K-75.6%	$536K+22.9%	$436K+143.3%	$179K
Free Cash Flow	N/A	-$2.3M-21.3%	-$1.9M	N/A	N/A	N/A	$803K+370.8%	-$297K-120.0%	$1.5M+1203.4%	$114K
Investing Cash Flow	-$1.3M-2069.5%	$64K+140.4%	$26K+314.8%	-$12K+73.8%	-$47K+99.2%	-$5.8M-5.6%	-$5.5M-801.0%	-$610K+41.9%	-$1.1M-464.0%	-$186K
Financing Cash Flow	$14.4M+71.8%	$8.4M+420.0%	-$2.6M-189.2%	$2.9M+84.4%	$1.6M-87.1%	$12.4M+310.3%	$3.0M-66.6%	$9.0M+2977.7%	-$314K-521.5%	-$51K

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23

Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

SXTC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

SXTC quarterly financial ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	21.9%+0.7pp	21.1%-7.6pp	28.7%+7.1pp	21.6%-26.5pp	48.1%-11.3pp	59.4%+7.1pp	52.4%-13.4pp	65.8%+17.3pp	48.5%+1.1pp	47.4%
Operating Margin	-625.9%	-154.0%	-130.4%	-284.4%	-199.4%	-46.0%-20.0pp	-26.0%-51.2pp	25.2%+2.0pp	23.3%-9.6pp	32.8%
Net Margin	-545.2%	-189.8%	-160.7%	-301.0%	-220.4%	-57.5%	-199.3%	21.9%+5.0pp	16.9%-7.4pp	24.3%
Return on Equity	-20.9%+0.5pp	-21.4%+0.8pp	-22.2%+18.2pp	-40.4%-4.7pp	-35.7%-18.5pp	-17.2%+92.2pp	-109.4%-123.3pp	13.9%-22.3pp	36.1%-27.8pp	64.0%
Return on Assets	-17.8%-2.6pp	-15.3%-1.8pp	-13.4%+6.7pp	-20.1%-3.0pp	-17.1%-9.2pp	-8.0%+39.4pp	-47.4%-56.2pp	8.8%-6.7pp	15.5%	N/A
Current Ratio	7.93+4.4x	3.54+1.9x	1.60+0.3x	1.350.0x	1.31+0.1x	1.25-0.4x	1.60-0.9x	2.47+1.1x	1.40	N/A
Debt-to-Equity	0.020.0x	0.010.0x	0.010.0x	0.01-1.1x	1.06+1.1x	0.000.0x	0.000.0x	0.00-1.3x	1.33	N/A
FCF Margin	N/A	-134.8%	-100.3%	N/A	N/A	N/A	15.6%+19.8pp	-4.2%-25.4pp	21.1%+18.8pp	2.3%

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23
Current Ratio	7.93+3.6x	4.37+0.8x	3.54+2.1x	1.40-0.2x	1.60+0.1x	1.47+0.1x	1.35-0.3x	1.70
Debt-to-Equity	0.020.0x	0.000.0x	0.010.0x	0.010.0x	0.010.0x	0.020.0x	0.01-0.5x	0.50

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.

Similar Companies

Ironwood IRWD

$700.6M

Journey Medical Corp DERM

$212.5M

Organigram Global Inc OGI

$173.4M

Alpha Teknova TKNO

$392.5M

BioAge Labs Inc. BIOA

$462.6M

Where China Sxt Pharmaceuticals Inc Ranks

Frequently Asked Questions

What is China Sxt Pharmaceuticals Inc's annual revenue?

China Sxt Pharmaceuticals Inc (SXTC) reported $1.1M in total revenue for fiscal year 2026. This represents a -34.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is China Sxt Pharmaceuticals Inc's revenue growing?

China Sxt Pharmaceuticals Inc (SXTC) revenue declined by 34.6% year-over-year, from $1.7M to $1.1M in fiscal year 2026.

Is China Sxt Pharmaceuticals Inc profitable?

No, China Sxt Pharmaceuticals Inc (SXTC) reported a net income of -$6.2M in fiscal year 2026.

What is China Sxt Pharmaceuticals Inc's EBITDA?

China Sxt Pharmaceuticals Inc (SXTC) had EBITDA of -$7.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does China Sxt Pharmaceuticals Inc have?

As of fiscal year 2026, China Sxt Pharmaceuticals Inc (SXTC) had $28.2M in cash and equivalents against $644K in long-term debt.

What is China Sxt Pharmaceuticals Inc's gross margin?

China Sxt Pharmaceuticals Inc (SXTC) had a gross margin of 21.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is China Sxt Pharmaceuticals Inc's return on equity (ROE)?

China Sxt Pharmaceuticals Inc (SXTC) has a return on equity of -20.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is China Sxt Pharmaceuticals Inc's operating cash flow?

China Sxt Pharmaceuticals Inc (SXTC) recorded an outflow of $4.0M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are China Sxt Pharmaceuticals Inc's total assets?

China Sxt Pharmaceuticals Inc (SXTC) had $34.8M in total assets as of fiscal year 2026, including both current and long-term assets.

How many shares does China Sxt Pharmaceuticals Inc have outstanding?

China Sxt Pharmaceuticals Inc (SXTC) had 958,077 shares outstanding as of fiscal year 2026.

What is China Sxt Pharmaceuticals Inc's current ratio?

China Sxt Pharmaceuticals Inc (SXTC) had a current ratio of 7.93 as of fiscal year 2026, which is generally considered healthy.

What is China Sxt Pharmaceuticals Inc's debt-to-equity ratio?

China Sxt Pharmaceuticals Inc (SXTC) had a debt-to-equity ratio of 0.02 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is China Sxt Pharmaceuticals Inc's return on assets (ROA)?

China Sxt Pharmaceuticals Inc (SXTC) had a return on assets of -17.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

How does China Sxt Pharmaceuticals Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, China Sxt Pharmaceuticals Inc (SXTC) held $28.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.0M over that year. Dividing the one by the other, the reported balance equals about 84 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is China Sxt Pharmaceuticals Inc's Altman Z-Score?

China Sxt Pharmaceuticals Inc (SXTC) has an Altman Z-Score of -0.79, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is China Sxt Pharmaceuticals Inc's Piotroski F-Score?

China Sxt Pharmaceuticals Inc (SXTC) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are China Sxt Pharmaceuticals Inc's earnings high quality?

China Sxt Pharmaceuticals Inc (SXTC) reported a net loss of $6.2M while operations used $4.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can China Sxt Pharmaceuticals Inc cover its interest payments?

China Sxt Pharmaceuticals Inc (SXTC) reported an operating loss of $7.1M against $63K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is China Sxt Pharmaceuticals Inc?

China Sxt Pharmaceuticals Inc (SXTC) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.